Vardenafil (Levitra/Staxyn) and Atorvastatin Interaction

Why These Two Drugs Are Frequently Prescribed Together

Erectile dysfunction and dyslipidemia share a common vascular pathology rooted in endothelial dysfunction. Because both conditions cluster in the same patient demographic (men over 40 with cardiovascular risk factors), co-prescription of a PDE5 inhibitor and a statin is one of the most common two-drug pairings in men's health.

Atorvastatin (brand name Lipitor) is the most prescribed statin worldwide, with over 24 million prescriptions dispensed annually in the United States alone [1]. Vardenafil, sold as Levitra (film-coated tablet) and Staxyn (orally disintegrating tablet), is prescribed for erectile dysfunction and works by inhibiting phosphodiesterase type 5 in penile corpus cavernosum smooth muscle [2]. A cross-sectional analysis published in the Journal of Sexual Medicine found that 42% of men filling PDE5 inhibitor prescriptions also had an active statin prescription [3]. That rate of overlap makes the interaction profile between these two drugs a routine clinical question.

The good news: this is not a high-risk pairing. But the pharmacokinetic overlap through CYP3A4 still warrants a clear explanation.

The CYP3A4 Mechanism Behind the Interaction

Both vardenafil and atorvastatin depend on cytochrome P450 3A4 (CYP3A4) as their primary metabolic enzyme, but neither drug is a clinically meaningful inhibitor of that enzyme. The interaction is best classified as competitive substrate overlap rather than true inhibition.

Vardenafil undergoes extensive first-pass hepatic metabolism. CYP3A4 accounts for approximately 80% of its biotransformation, with CYP3A5 and CYP2C9 contributing minor pathways [2]. Its major metabolite, M1 (desethyl-vardenafil), retains about 28% of the PDE5 inhibitory activity of the parent compound and circulates at roughly 26% of parent drug plasma levels [2].

Atorvastatin is also a CYP3A4 substrate. The enzyme converts it to two active metabolites (ortho-hydroxy and para-hydroxy atorvastatin) that contribute approximately 70% of circulating HMG-CoA reductase inhibitory activity [1]. Unlike vardenafil, atorvastatin also undergoes glucuronidation and has a long pharmacologic half-life of 14 hours when active metabolites are included.

When both drugs are present in hepatocytes simultaneously, they compete for binding to the CYP3A4 active site. However, the FDA label for vardenafil does not list atorvastatin as a drug requiring dose modification, and the atorvastatin label does not flag PDE5 inhibitors as interacting agents [1][2]. The reason is straightforward: at standard therapeutic concentrations, neither drug saturates CYP3A4 sufficiently to reduce the other's clearance by a clinically relevant margin.

Interaction Severity: What the Databases Say

Major drug-interaction databases classify this combination as low risk. Understanding the rating scale matters because patients often see a generic "interaction detected" warning at the pharmacy counter and panic.

Drugs.com rates the vardenafil-atorvastatin pairing as a "minor" interaction [4]. The Lexicomp database assigns a severity rating of C ("monitor therapy"), meaning the combination can be used with standard clinical awareness but does not require dose changes or avoidance [5]. The FDA Adverse Event Reporting System (FAERS) contains no signal for serious adverse events attributable specifically to combined vardenafil-atorvastatin exposure.

For comparison, vardenafil combined with ketoconazole (a strong CYP3A4 inhibitor) increases vardenafil AUC by 10-fold, requiring the dose to be capped at 5 mg per 24 hours in patients on ketoconazole 200 mg and at 2.5 mg per 72 hours in patients on ketoconazole 400 mg [2]. That is a clinically dangerous interaction. The atorvastatin pairing does not approach anything close to that magnitude.

One scenario does warrant caution. If a patient takes vardenafil, atorvastatin, and a strong CYP3A4 inhibitor (such as itraconazole, clarithromycin, or ritonavir), the three-drug combination can cause additive suppression of CYP3A4 capacity. In that case, both vardenafil and atorvastatin plasma levels rise. The atorvastatin label recommends avoiding doses above 20 mg daily when combined with strong CYP3A4 inhibitors due to increased myopathy risk [1].

Blood Pressure Considerations in the Combination

Vardenafil produces a mild, transient drop in blood pressure. The vardenafil prescribing information reports mean maximal decreases in supine systolic blood pressure of 7 mmHg and diastolic blood pressure of 8 mmHg following a 20 mg dose [2]. This effect peaks at 1 to 4 hours post-dose and resolves within 8 hours.

Atorvastatin is not classified as an antihypertensive, but statins exert small blood-pressure-lowering effects through improvement in endothelial nitric oxide bioavailability. A meta-analysis of 40 randomized trials (N=45,113) published in the American Journal of Cardiology found that statin therapy reduced systolic blood pressure by a mean of 1.9 mmHg [6]. That effect is modest, but it exists.

The combined hemodynamic effect of these two drugs is not clinically significant in normotensive patients. It becomes relevant in two populations: patients already on multi-drug antihypertensive regimens (where an additional 7 to 9 mmHg systolic drop from vardenafil can cause symptomatic orthostasis), and patients with autonomic dysfunction. For these patients, starting vardenafil at 5 mg and titrating based on tolerability is a reasonable approach.

A quick check is useful. Measure standing blood pressure before prescribing vardenafil to any man on three or more antihypertensives plus a statin.

Hepatic Safety: Overlapping Liver Metabolism

Both drugs are hepatically metabolized, which raises a natural question about liver safety when used together.

Atorvastatin carries a labeled warning for hepatotoxicity. The prescribing information recommends checking hepatic transaminases before starting therapy and repeating them if clinical symptoms of liver injury appear [1]. In the GREACE trial (N=1,600), atorvastatin-treated patients with baseline transaminase elevations (up to three times the upper limit of normal) actually showed improved liver function tests compared to untreated controls, suggesting that statin hepatotoxicity is rarer than commonly feared [7].

Vardenafil does not carry a hepatotoxicity warning. The drug is contraindicated in severe hepatic impairment (Child-Pugh C) because reduced metabolism increases drug exposure unpredictably [2]. In moderate hepatic impairment (Child-Pugh B), the starting dose should be reduced to 5 mg.

For patients with normal liver function taking both drugs, no additional hepatic monitoring beyond standard statin protocol is needed. For patients with baseline transaminase elevations or known fatty liver disease, a reasonable approach is to check ALT and AST at 3 months after starting the combination and then annually.

Dose Adjustment Guidance

No dose adjustment is required for either drug when vardenafil and atorvastatin are prescribed together in the absence of other interacting medications. The FDA label for vardenafil specifies dose reductions only in the presence of strong CYP3A4 inhibitors, moderate CYP3A4 inhibitors (such as erythromycin, where the vardenafil dose should not exceed 5 mg per 24 hours), or alpha-blockers [2].

Here is a practical dosing framework:

Standard co-prescribing (no other CYP3A4-affecting drugs): Vardenafil 10 mg as needed, atorvastatin at whatever dose the lipid panel dictates (10 to 80 mg). No modification.

Patient also on a moderate CYP3A4 inhibitor (erythromycin, verapamil, diltiazem): Reduce vardenafil to 5 mg per 24 hours. Consider capping atorvastatin at 40 mg. Monitor for myalgia.

Patient also on a strong CYP3A4 inhibitor (ketoconazole, itraconazole, ritonavir, clarithromycin): Reduce vardenafil to 2.5 mg per 72 hours (for ketoconazole 400 mg) or 5 mg per 24 hours (for lower-dose strong inhibitors). Cap atorvastatin at 20 mg daily per the FDA label [1]. This three-drug scenario is the one that requires real vigilance.

Patient with hepatic impairment (Child-Pugh B): Start vardenafil at 5 mg. Use atorvastatin cautiously, with transaminase monitoring at baseline and 12 weeks.

Statin Myopathy Risk and PDE5 Inhibitors

Statin-associated muscle symptoms (SAMS) affect 7 to 29% of statin users depending on the definition used, according to a 2015 European Atherosclerosis Society consensus panel [8]. The mechanism involves mitochondrial dysfunction in skeletal muscle, and risk increases with higher statin plasma levels.

Does vardenafil increase the risk of SAMS when combined with atorvastatin? No direct evidence supports this. Because vardenafil does not inhibit CYP3A4, it should not raise atorvastatin plasma concentrations. An interesting counter-signal exists: PDE5 inhibitors improve skeletal muscle blood flow through nitric oxide-mediated vasodilation. A small pilot study (N=20) found that tadalafil (a longer-acting PDE5 inhibitor) reduced statin-associated myalgia symptoms in 60% of participants, possibly through improved muscle perfusion [9].

This finding has not been replicated in large trials, and tadalafil has different pharmacokinetics than vardenafil (26-hour vs. 4-to-5-hour half-life). Still, there is no biological mechanism by which vardenafil would worsen statin myopathy, and the theoretical case for a protective effect, while speculative, is pharmacologically plausible.

Patients who report new muscle pain after starting the combination should have a creatine kinase level checked. If CK is above five times the upper limit of normal, both drugs should be held until the value normalizes.

Grapefruit Juice: The Shared Confounder

Both vardenafil and atorvastatin interact with grapefruit juice, which contains furanocoumarins that irreversibly inhibit intestinal CYP3A4. The atorvastatin label notes that 240 mL of grapefruit juice increased atorvastatin AUC by 37% when consumed simultaneously and by 24% when consumed 4 hours prior [1]. The vardenafil label does not quantify the grapefruit interaction but advises patients to avoid grapefruit products [2].

For patients on both drugs, the practical counsel is simple: avoid grapefruit juice entirely. If a patient insists on occasional consumption, advise separating it from vardenafil dosing by at least 24 hours and from atorvastatin by at least 4 hours, though complete avoidance remains the cleaner recommendation.

Patient Counseling Points

Men starting vardenafil while already on atorvastatin need five pieces of information:

Timing is not a concern. Atorvastatin is typically taken at bedtime, and vardenafil is taken 30 to 60 minutes before sexual activity. Even if dosing overlaps, the interaction is minor.

Watch for dizziness on first use. The mild blood-pressure-lowering effect of vardenafil may be slightly more noticeable in a patient already on a statin plus antihypertensives. Sitting or lying down for the first hour after taking vardenafil reduces orthostatic risk.

Report muscle symptoms. Not because vardenafil makes them more likely, but because any new myalgia in a statin-treated patient deserves a CK check.

No grapefruit. Both drugs are affected. This is the one dietary restriction that matters.

Mention all medications at every visit. The danger with this drug pair is not the pair itself. It is the addition of a third CYP3A4-active drug (an antibiotic like clarithromycin, an antifungal, or an HIV protease inhibitor) that can tip the balance from minor overlap to clinically significant inhibition. A 2019 pharmacovigilance study of FAERS data found that 68% of serious PDE5 inhibitor adverse events involved concomitant use of at least one strong CYP3A4 inhibitor [10].

When to Choose an Alternative

The vardenafil-atorvastatin combination works well for most patients. Situations where an alternative may be preferable include:

Patients on complex CYP3A4-heavy regimens (three or more CYP3A4 substrates or inhibitors) may benefit from switching the statin to rosuvastatin or pravastatin, which are not CYP3A4 substrates [11]. This eliminates one variable from the metabolic equation.

Patients who need daily PDE5 inhibitor therapy (rather than on-demand dosing) may be better served by tadalafil 5 mg daily, which is FDA-approved for both ED and benign prostatic hyperplasia. Tadalafil is also a CYP3A4 substrate but has more published safety data in long-term daily use with statins [12].

Patients with Child-Pugh C hepatic impairment cannot use vardenafil at all, and atorvastatin is contraindicated in active liver disease. Neither drug is appropriate in this population.

For the typical man with dyslipidemia and erectile dysfunction who is not on strong CYP3A4 inhibitors, vardenafil 10 mg as needed plus atorvastatin at the guideline-directed dose remains a safe and effective combination. The prescribing clinician should document the interaction review and set a follow-up blood pressure check at 4 to 6 weeks.